RxDoctor Payments Data

Jean-Nicolas Vauthey, MD

Surgical Oncology · Houston, TXNPI 1104912989

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $11,501 of the $13,330 with a category attached, or 86.3%. Siemens Medical Solutions USA, Inc. accounts for 86.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $11,883 and has fallen 96.7% since, to $392 in 2025.

$13,330in general payments, 2019–2025

Across 20 payments — averaging $666.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$12K
  • Medtronic$500
  • Johnson & Johnson$466
  • Integra Lifesciences Corporation$339
  • Fujifilm Healthcare Americas Corporation$167
  • Intera Oncology, Inc$156
  • plus $164 from 3 others
$143,424in research payments, 2019–2025

Across 5 payments — averaging $28,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$140K
  • Fujifilm Healthcare Americas Corporation$4K

What the payments were for

  • Travel & lodging$11,50186%
  • Food & beverage$1,82914%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,330 in reported general payments places this provider in the 85th percentile of 191 surgical oncology providers in Texas.

See all surgical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$64,809
Medicare patients
71
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →